This Week: and lots more… Earlier this month, Boston-based drug developer Delix Therapeutics announced that a Phase 1 study of its DLX-001 candidate has commenced.The trial will seek to enrol around 100 healthy volunteers at the Centre for Human Drug Research in the Netherlands.As we have covered previously, Delix is hoping that its non-hallucinogenic compounds will maintain some of the apparent…


Previous articlePT412 – Psychedelics and Virtual Reality: Where Novel Experience, Technology, and Altered States of Consciousness Meet
Next articleCOMPASS Pathways’ Co-Founder Ekaterina Malievskaia to Step Down as Chief Innovation Officer